Evolent Health, Inc $EVH Stake Lowered by Engaged Capital LLC

Engaged Capital LLC decreased its holdings in shares of Evolent Health, Inc (NYSE:EVH) by 4.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,179,468 shares of the technology company’s stock after selling 225,300 shares during the quarter. Evolent Health makes up approximately 12.5% of Engaged Capital LLC’s portfolio, making the stock its 5th biggest position. Engaged Capital LLC’s holdings in Evolent Health were worth $49,050,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Banque Cantonale Vaudoise acquired a new stake in Evolent Health during the first quarter worth approximately $25,000. US Bancorp DE grew its position in shares of Evolent Health by 291.0% in the 1st quarter. US Bancorp DE now owns 5,153 shares of the technology company’s stock valued at $49,000 after buying an additional 3,835 shares during the last quarter. Signaturefd LLC raised its stake in Evolent Health by 400.6% during the 1st quarter. Signaturefd LLC now owns 7,043 shares of the technology company’s stock worth $67,000 after acquiring an additional 5,636 shares in the last quarter. GAMMA Investing LLC lifted its position in Evolent Health by 5,036.4% in the first quarter. GAMMA Investing LLC now owns 9,451 shares of the technology company’s stock valued at $90,000 after acquiring an additional 9,267 shares during the last quarter. Finally, State of Wyoming acquired a new position in Evolent Health in the fourth quarter valued at $95,000.

Wall Street Analysts Forecast Growth

EVH has been the subject of a number of research reports. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price objective on shares of Evolent Health in a research note on Tuesday, May 13th. JMP Securities reaffirmed a “market outperform” rating and issued a $13.00 target price on shares of Evolent Health in a report on Friday, June 20th. Piper Sandler increased their price target on shares of Evolent Health from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Thursday, August 28th. UBS Group raised their price objective on shares of Evolent Health from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, May 9th. Finally, Truist Financial upped their target price on shares of Evolent Health from $14.00 to $16.00 and gave the company a “buy” rating in a report on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Evolent Health presently has a consensus rating of “Buy” and a consensus target price of $18.07.

Evolent Health Trading Down 0.5%

NYSE:EVH opened at $9.57 on Thursday. Evolent Health, Inc has a 1 year low of $7.06 and a 1 year high of $31.80. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.01 and a current ratio of 1.01. The stock has a fifty day moving average price of $10.10 and a two-hundred day moving average price of $9.54. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of -5.94 and a beta of 0.73.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Thursday, August 7th. The technology company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.20). Evolent Health had a positive return on equity of 1.83% and a negative net margin of 5.94%.The company had revenue of $444.33 million for the quarter, compared to analysts’ expectations of $459.43 million. During the same period in the prior year, the firm posted $0.30 EPS. The firm’s quarterly revenue was down 31.3% on a year-over-year basis. Evolent Health has set its Q3 2025 guidance at EPS. As a group, sell-side analysts anticipate that Evolent Health, Inc will post 0.08 earnings per share for the current fiscal year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.